Gilead Sciences Inc. (GILD)
GILD's Q4 Earnings Beat Estimates, HIV and Liver Disease Drugs Power Sales
Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.
Gilead Sciences Stock Surges to Record Highs Amid Bull Notes
Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $1.86 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.9 per share a year ago.
Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Gilead quarterly results beat Wall Street estimates
Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026 financial forecast was at the lower end of analysts' expectations.
Gilead Sciences: Buy This Stock For Both Dividend And Growth
I rate Gilead Sciences (GILD) a 'Buy' with a $191 price target. It offers an attractive 2.1% dividend yield and low volatility. GILD's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk versus peers. Strong profitability, efficient capital allocation, and robust dividend growth capacity underpin GILD's investment case for safety and income.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?
GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.23, denoting a +2.06% move from the preceding trading day.
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
